D. E. Shaw & Co. Inc. Lowers Position in Design Therapeutics, Inc. (NASDAQ:DSGN)

D. E. Shaw & Co. Inc. cut its holdings in shares of Design Therapeutics, Inc. (NASDAQ:DSGN) by 12.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 512,330 shares of the company’s stock after selling 70,528 shares during the quarter. D. E. Shaw & Co. Inc. owned about 0.90% of Design Therapeutics worth $3,161,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. Invesco Ltd. purchased a new position in shares of Design Therapeutics during the 4th quarter worth $71,000. China Universal Asset Management Co. Ltd. purchased a new position in Design Therapeutics during the 4th quarter valued at about $74,000. Kennedy Capital Management LLC purchased a new position in Design Therapeutics during the 4th quarter valued at about $88,000. Intech Investment Management LLC acquired a new stake in Design Therapeutics in the 4th quarter valued at about $109,000. Finally, Wells Fargo & Company MN raised its position in Design Therapeutics by 27.8% in the 4th quarter. Wells Fargo & Company MN now owns 18,428 shares of the company’s stock valued at $114,000 after purchasing an additional 4,013 shares in the last quarter. 56.64% of the stock is currently owned by hedge funds and other institutional investors.

Design Therapeutics Stock Performance

Shares of NASDAQ DSGN opened at $3.51 on Monday. Design Therapeutics, Inc. has a fifty-two week low of $2.60 and a fifty-two week high of $7.77. The firm has a market capitalization of $199.26 million, a PE ratio of -4.13 and a beta of 1.77. The stock’s 50-day simple moving average is $3.88 and its 200-day simple moving average is $4.88.

Design Therapeutics (NASDAQ:DSGN) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.03). On average, sell-side analysts forecast that Design Therapeutics, Inc. will post -0.91 earnings per share for the current fiscal year.

About Design Therapeutics

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.